Recent articles for private investors with a focus on dividend announcements
Schroders increases its 2015 interim dividend by 21%
Profit before tax and exceptional items up 17 per cent. to £305.7 million (H1 2014: £261.5 million)
Money supermarket increses its 2015 interim dividend by 10%
Insurance revenues up 8% with car insurance premiums starting to show a marginal increase.
Royal Dutch Shell 2015 interim results
Royal Dutch Shell’s second quarter 2015 earnings, on a current cost of supplies (CCS) basis (see Note 2), were $3.4 billion compared with $5.1 billion for the same quarter a year ago.
Law debenture Group 2015 interim results
HALF YEARLY REPORT FOR THE SIX MONTHS TO 30 JUNE 2015 (unaudited)
Capital and Counties 2015 interim results
Highlights Driving value creation through a clear and focused strategy
GlaxoSmithKline 2015 Q2 results
Summary
·
Group sales +7% CER on a reported basis and +2% CER pro-forma
-
Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma)
-
New Pharmaceutical and Vaccine sales of £446 million in Q2
·
Q2 core EPS of 17.3p, flat in CER terms
-
EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions
-
Integration of new Consumer and Vaccine businesses on track
-
On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes
·
Total Q2 EPS of 3.1p and H1 EPS of 170.7p
-
Reflects phasing of pre-tax transaction gains and accelerated restructuring charges
·
2015 earnings guidance and 2016 outlook reiterated
-
Expect 2015 core EPS to decline at a high teen percentage rate (CER)
-
2016 core EPS percentage growth expected to reach double digits (CER)
·
Q2 dividend of 19p declared
-
Continued expectation for full year dividend of 80p
·
R&D innovation with significant potential to drive long-term Group performance
-
Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan
-
Positive CHMP decision received for Mosquirix
-
Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases
-
New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
Jupiter fund management increases its 2015 interim dividend by 8.1%
Continued organic flow growth from our core mutual fund franchise, with net mutual fund inflows of £1.4bn
National Express increases its 2015 interim dividend by 10%
Half Year Results for the six months ended 30 June 2015
St James's place increases its 2015 interim dividend by 20%
New Investment and Funds under Management
Pace passes on its 2015 interim dividend due to Arris merger
Solid H1 2015: Gross margin up 1.6ppt to 23.2%, operating margin up 1.6ppt to 10.9% and adjusted basic EPS up 11.4% to 28.4c. Strong H2 2015 anticipated and the proposed combination with ARRIS Group is progressing in-line with expectations.
BP maintains its 2015 Q2 dividend in $ terms at 10 cents
BP's second-quarter replacement cost (RC) loss was $6,266 million, compared with a profit of $3,182 million a year ago. After adjusting for a net charge for non-operating items of $7,486 million, mainly relating to the recently announced agreements in principle to settle federal, state and the vast majority of local government claims arising from the 2010 Deepwater Horizon accident, and net unfavourable fair value accounting effects of $93 million (both on a post-tax basis), underlying RC profit for the second quarter was $1,313 million, compared with $3,635 million for the same period in 2014. For the half year, RC loss was $4,163 million, compared with a profit of $6,657 million a year ago. After adjusting for a net charge for non-operating items of $7,899 million and net unfavourable fair value accounting effects of $154 million (both on a post-tax basis), underlying RC profit for the half year was $3,890 million, compared with $6,860 million for the same period in 2014. Non-operating items include a restructuring charge of $272 million for the quarter and $487 million for the half year. Restructuring charges are now expected to be around $1.5 billion by the end of 2015 relative to the $1 billion we announced back in December. RC profit or loss for the group, underlying RC profit or loss and fair value accounting effects are non-GAAP measures and further information is provided on pages 3 and 30.
Segro increases its 2015 interim dividend by 2%
IFRS profit before tax increased to £330.0 million (H1 2014: £226.5 million) and Adjusted profit before tax1 increased to £69.2 million (H1 2014: £66.7 million).
Dialight cuts its 2015 interim dividend
Lighting revenue increased 24% (17% at constant currency) to £53.4m (H1 2014: £43.0m)
Senior increases its 2015 interim dividend by 10%
Interim Results for the half-year ended 30 June 2015
Hammerson increases its 2015 interim dividend by 8%
Operational highlights - consistent income generation
4701-4750 of 7431
